Expert hematologist/oncologists review key datasets in leukemia presented at the ASH 2022 Annual Meeting.
Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.
EP. 1: ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape
Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.
EP. 2: ASH 2022: Recent Advances in Chronic Myeloid Leukemia
Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.
EP. 3: Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting
Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC